Bank of New York Mellon
CRBU icon

Bank of New York Mellon’s Caribou Biosciences CRBU Stock Holding History

Bank of New York Mellon’s Portfolio CRBU Stock Details CRBU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$392K Buy
222,560
+210,049
+1,679% +$415K ﹤0.01% 3867
2026
Q1 		$23.8K Sell
12,511
-445
-3% -$764 ﹤0.01% 4172
2025
Q4 		$20.6K Sell
12,956
-1,095
-8% -$2.3K ﹤0.01% 4166
2025
Q3 		$32.7K Buy
14,051
+38
+0.3% +$72 ﹤0.01% 4147
2025
Q2 		$17.7K Sell
14,013
-210,373
-94% -$207K ﹤0.01% 4118
2025
Q1 		$205K Sell
224,386
-631
-0.3% -$820 ﹤0.01% 3881
2024
Q4 		$358K Sell
225,017
-15,809
-7% -$31.8K ﹤0.01% 3689
2024
Q3 		$472K Sell
240,826
-67,447
-22% -$138K ﹤0.01% 3554
2024
Q2 		$506K Buy
308,273
+38,098
+14% +$122K ﹤0.01% 3584
2024
Q1 		$1.39M Sell
270,175
-25,059
-8% -$155K ﹤0.01% 2971
2023
Q4 		$1.69M Buy
295,234
+30,991
+12% +$153K ﹤0.01% 2913
2023
Q3 		$1.26M Buy
264,243
+60,242
+30% +$374K ﹤0.01% 3034
2023
Q2 		$867K Buy
204,001
+18,007
+10% +$80.9K ﹤0.01% 3284
2023
Q1 		$988K Sell
185,994
-3,350
-2% -$20.9K ﹤0.01% 3134
2022
Q4 		$1.19M Buy
189,344
+7,873
+4% +$70.1K ﹤0.01% 3106
2022
Q3 		$1.91M Buy
181,471
+34,286
+23% +$319K ﹤0.01% 2883
2022
Q2 		$799K Buy
147,185
+5,923
+4% +$45.3K ﹤0.01% 3320
2022
Q1 		$1.3M Buy
141,262
+73,427
+108% +$774K ﹤0.01% 3150
2021
Q4 		$1.02M Buy
67,835
+19,704
+41% +$383K ﹤0.01% 3377
2021
Q3 		$1.15M Buy
+48,131
New +$1.18M ﹤0.01% 3312

Other funds holding CRBU

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
MAM
Milestone Asset Management Pittsburgh, Pennsylvania $636M AUM 22.1% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return
KFGK
Keystone Financial Group (Kentucky) Lexington, Kentucky $1.69B AUM 40.17% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Bank of New York Mellon's CRBU Position: Q2 2026 in Review

Bank of New York Mellon increased its Caribou Biosciences (CRBU) stake by 1,679% in Q2 2026, buying an estimated $415K and bringing the position to 222,560 shares worth $392K. The position accounts for ﹤0.01% of the portfolio, ranked #3867.

Bank of New York Mellon first reported a position in CRBU in Q3 2021 and has held it in 20 quarters since. The position peaked at $1.91M in Q3 2022. 51 funds tracked by Wall St. Rank hold CRBU as of Q2 2026.

  • Bank of New York Mellon held 222,560 shares of Caribou Biosciences worth $392K as of Q2 2026.
  • Bank of New York Mellon bought 210,049 Caribou Biosciences shares in Q2 2026, an estimated $415K.
  • Caribou Biosciences made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #3867 holding.
  • Bank of New York Mellon first reported a position in Caribou Biosciences in Q3 2021 and has held it in 20 quarters since.
  • Bank of New York Mellon's Caribou Biosciences position peaked at $1.91M in Q3 2022.
  • 51 funds tracked by Wall St. Rank held Caribou Biosciences as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.